Government Price Setting Threatens Patient Access to Treatments



Some in Congress continue to push government price setting proposals that, if implemented, would chill innovation and threaten access to future medicines. In other countries where similar policies have been implemented, patients have access to fewer new medicines. Here are some examples.

| | | | * * | * | | | | |
|----------|---|------------------|-----------|--------|--------|---------|-------|-------------------|
| | | United States | Australia | Canada | France | Germany | Japan | United Kingdom |
| į. | Of the 460 new medicines approved globally since 2012, what percentage are available? | 85% | 34% | 44% | 50% | 61% | 51% | 59% |
| | Of the 123 new cancer medicines approved globally since 2012, what percentage are available abroad? | 93% | 38% | 59% | 64% | 71% | 54% | 69% |
| 4 | Of the 69 new anti- infectives and antivirals approved globally since 2012, what percentage are available abroad? | 86% | 41% | 41% | 65% | 58% | 46% | 62% |
| 6 | Of the 13 new respiratory medicines approved globally since 2012, what percentage are available abroad? | 100% | 69% | 69% | 77% | 85% | 46% | 85% |
| ~ | Of the 19 new cardiovascular medicines approved globally since 2012, what percentage are available abroad? | 79% | 32% | 37% | 37% | 63% | 58% | 58% |